William Blair on Tarsus Pharmaceuticals (TARS): 'benefits from the large and motivated patient population'

March 23, 2026 9:51 AM

William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Tarsus Pharmaceuticals (NASDAQ: TARS).The analyst comments "We believe the impressive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found